Keywords
Septic shock
Pediatrics
How to Cite
Abstract
Introduction: despite the progress made in critical care in recent years, septic shock continues to be a significant cause of morbidity and mortality in pediatrics (ref). The administration of Vasopressin and Terlipressin (AVP/TP) has been documented to show good response in adult patients with septic shock. In pediatrics, its effect on morbidity and mortality is still poorly studied and controversial. We propose to analyze the current evidence for the use of AVP and TP in critically ill pediatric patients based on the presentation of two clinical cases.
Clinical Cases: we present the clinical records of two pediatric patients, aged 11 and 14, admitted to the PICU with a diagnosis of Septic Shock. Both showed a similar hemodynamic profile with resistance to catecholamine treatment, and in both, Vasopressin was used as a rescue vasopressor.
Discussion: vasopressin is a hormone that, in physiological situations, actively participates in determining plasma osmolarity, maintaining volume status, and blood pressure. During septic shock, a decrease in its plasma concentration has been observed, which could explain catecholamine resistance and the refractory profile of the shock. We reviewed the evidence in adults and children analyzing the use of this drug under these circumstances.
Conclusions: treatment with AVP/TP in pediatric patients with refractory septic shock could improve the hemodynamic profile and reduce the requirement for other inotropes and vasopressors at high doses. However, to date, there is no evidence of its use in pediatrics decreasing morbidity, mortality, or hospital stays.
References
Alder M, Bodilly L, Wong H. Pediatric sepsis. En: Zimmerman JJ, Rotta A. Fuhrman and Zimmerman’s Pediatric Critical Care. 6ed. Filadelfia: Elsevier; 2022:1293-309.
Schlapbach L, Watson R, Sorce L, Argent A, Menon K, Hall M, et al. International consensus criteria for pediatric sepsis and septic shock. JAMA 2024; 331(8):665-74. doi: 10.1001/jama.2024.0179.
Hurtado F, Lacuesta G, Baz M. Fisiopatología de los estados de shock. En: Artucio H, Rieppi G. Medicina intensiva cardiovascular. Montevideo: Oficina del libro-FEFMUR, 2010:223-64.
García P, Tonial C, Piva J. Septic shock in pediatrics: the state-of-the-art. J Pediatr (Rio J) 2020; 96(Suppl 1):87-98. doi: 10.1016/j.jped.2019.10.007.
Weiss S, Peters M, Alhazzani W, Agus M, Flori H, Inwald D, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatr Crit Care Med 2020; 21(2):e52-e106. doi: 10.1097/PCC.0000000000002198.
Choong K, Kissoon N. Vasopressin in pediatric shock and cardiac arrest. Pediatr Crit Care Med 2008; 9(4):372-9. doi: 10.1097/PCC.0b013e318172d7c8.
Meyer S, McGuire W, Gottschling S, Mohammed G, Gortner L. The role of vasopressin and terlipressin in catecholamine-resistant shock and cardio-circulatory arrest in children: review of the literature. Wien Med Wochenschr 2011; 161(7-8):192-203. doi: 10.1007/s10354-010-0853-7.
Davis A, Carcillo J, Aneja R, Deymann A, Lin J, Nguyen T, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med 2017; 45(6):1061-93. doi: 10.1097/CCM.0000000000002425.
Huang L, Zhang S, Chang W, Xia F, Liu S, Yang Y, et al. Terlipressin for the treatment of septic shock in adults: a systematic review and meta-analysis. BMC Anesthesiol 2020; 20(1):58. doi: 10.1186/s12871-020-00965-4.
Organización Mundial de la Salud. Sepsis. Ginebra: OMS, 2024. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/sepsis. (Consulta 9 setiembre 2024).
Baique P. Sepsis en pediatría: nuevos conceptos. An Fac Med 2017; 78(3):333-42. doi: 10.15381/anales.v78i3.13769.
Agrawal A, Singh V, Varma A, Sharma R. Therapeutic applications of vasopressin in pediatric patients. Indian Pediatr 2012; 49(4):297-305. doi: 10.1007/s13312-012-0046-0.
Choong K. Vasopressin in pediatric critical care. J Pediatr Intensive Care 2016; 5(4):182-8. doi: 10.1055/s-0036-1583282.
Chichizola N, Lureyro J, Bonaccorsi H. Utilización de vasopresina en el síndrome vasopléjico luego de cirugía cardiovascular. Anu Fund Dr JR Villavicencio 2012; 20:145-9. Disponible en: https://www.villavicencio.org.ar/ALMACEN/archivos/publicaciones_00000000680.pdf. (Consulta 9 setiembre 2024).
Masutani S, Senzaki H, Ishido H, Taketazu M, Matsunaga T, Kobayashi T, et al. Vasopressin in the treatment of vasodilatory shock in children. Pediatr Int 2005; 47(2):132-6. doi: 10.1111/j.1442-200x.2005.02043.x.
Ceneviva G, Paschall J, Maffei F, Carcillo J. Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 1998; 102(2):e19. doi: 10.1542/peds.102.2.e19.
Torgersen C, Dünser M, Wenzel V, Jochberger S, Mayr V, Schmittinger C, et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med 2010; 36(1):57-65. doi: 10.1007/s00134-009-1630-1.
Russell J, Walley K, Singer J, Gordon A, Hébert P, Cooper D, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358(9):877-87. doi: 10.1056/NEJMoa067373.
Masutani S, Senzaki H, Ishido H, Taketazu M, Matsunaga T, Kobayashi T, et al. Vasopressin in the treatment of vasodilatory shock in children. Pediatr Int 2005; 47(2):132-6. doi: 10.1111/j.1442-200x.2005.02043.x.
Michel J, Hofbeck M, Spiller G, Renk H, Kumpf M, Neunhoeffer F. Safety and efficacy of terlipressin in pediatric distributive shock: a retrospective analysis in 20 children. Paediatr Drugs 2017; 19(1):35-41. doi: 10.1007/s40272-016-0199-8.
Masarwa R, Paret G, Perlman A, Reif S, Raccah B, Matok I. Role of vasopressin and terlipressin in refractory shock compared to conventional therapy in the neonatal and pediatric population: a systematic review, meta-analysis, and trial sequential analysis. Crit Care 2017; 21(1):1. doi: 10.1186/s13054-016-1589-6.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Joaquin Perez, Juan Guerrero, Hector Telechea